More than two decades ago , Novartis made a big contribution to the fight against malaria when it won approval for Coartem, the first artemisinin-based combination therapy (ACT), which has transformed care for people with the parasitic infection.
Novartis, the world's second largest pharmaceutical company, has announced that its antimalarial medicine Coartem 80/480mg received World Health Organisation (WHO) prequalification, making it the first and only high strength (80/480mg) artemisinin-based combination therapy (ACT) antimalarial treatment available for public sector procurement.
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
Animal testing hits China social media with clothesline cats
Malaria combination drug therapy for children